精彩内容近日,东阳光药的舒更葡糖钠注射液获批上市,该产品是公司今年首个获批的仿制药新品。舒更葡糖钠注射液是解毒药TOP1产品,2024年在中国公立医疗机构终端的销售额达到了9.6亿元。据统计,东阳光药还有4款新药和4款仿制药新品报产在审。图1:东阳光药最新获批的产品来源:国家药监局官网舒更葡糖钠注射液是默沙东开发的首个用于逆转神经肌肉阻滞剂的选择性松弛拮抗剂,米内网数据显示,目前已有20多家国内...
Source Link精彩内容近日,东阳光药的舒更葡糖钠注射液获批上市,该产品是公司今年首个获批的仿制药新品。舒更葡糖钠注射液是解毒药TOP1产品,2024年在中国公立医疗机构终端的销售额达到了9.6亿元。据统计,东阳光药还有4款新药和4款仿制药新品报产在审。图1:东阳光药最新获批的产品来源:国家药监局官网舒更葡糖钠注射液是默沙东开发的首个用于逆转神经肌肉阻滞剂的选择性松弛拮抗剂,米内网数据显示,目前已有20多家国内...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.